Document:

Document

FIRST AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT

This first amendment (the “First Amendment”) to the Confidential Consulting Agreement dated June 3, 2020 (the “Agreement”) by and between the parties hereto, is executed as of the date shown on the signature page (the “Effective Date”), by and between FLG Partners, LLC, a California limited liability company (“FLG”), and Angion Biomedica Corp. (“Client”).
RECITALS
WHEREAS, FLG is in the business of providing certain financial services; and
WHEREAS, Client wishes to retain FLG to provide and FLG wishes to provide such services to Client on the terms set forth herein; and
WHEREAS, FLG has been continuously retained by Client since June 3rd and
WHEREAS, the parties hereto wish to extend the term of the Agreement;
NOW, THEREFORE, in consideration of the mutual covenants set forth herein, the parties hereto agree as follows:

    Page 1 of #NUM_PAGES#    200909 FLG-Angion First Amendment to Agreement.docx

FIRST AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT

1.Additional Compensation.      Exhibit A of the Agreement is amended to add “7. Additional Compensation: Non-qualified Common stock purchase options (the “Options”) equal to 36,000 shares. The exercise price per share of the Options (as determined by Client’s Board of Directors) shall be computed pursuant to and consistent with Client’s IRC §409A per share common stock valuation (the “Common Stock Value”) as of the grant date of the Options. 9,000 of the Options shall be vested upon grant, with the balance vesting ratably over the subsequent nine (9) months. Vesting of the Options shall cease upon termination of the Agreement, and the Options shall be exercisable for one (1) year after termination of the Agreement. Subject to compliance with applicable federal and state securities laws and regulations, the Options shall be issued 95% in the name of FLG Member and 5% in the name of FLG, each rounded to the nearest whole number of shares subject to the Options. 
2.Miscellaneous.    All other terms and conditions of the Agreement remain unchanged.  This First Amendment shall be incorporated in the Agreement as Exhibit B.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Effective Date.

						
	CLIENT:
Angion Biomedica Corp.,
a Delaware corporation.
By:    Jay Venkatesan
Signed:        
Title:    Chief Executive Officer 
Address:    51 Charles Lindbergh Boulevard
    Uniondale, NY 11553
Tel:    (415) 655-4899
Email:    jrv@angion.com
	FLG:
FLG Partners, LLC, 
a California limited liability company.
By:    Jeffrey S. Kuhn
Signed:        
Title:    Administrative Partner

Effective Date:    September 9, 2020

    Page 2 of #NUM_PAGES#    200909 FLG-Angion First Amendment to Agreement.docxDocument

SECOND AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT

This second amendment (the “Second Amendment”) to the Confidential Consulting Agreement dated June 3, 2020 (the “Agreement”) by and between the parties hereto, is executed as of the date shown on the signature page (the “Effective Date”), by and between FLG Partners, LLC, a California limited liability company (“FLG”), and Angion Biomedica Corp. (“Client”).
RECITALS
WHEREAS, FLG is in the business of providing certain financial services; and
WHEREAS, Client wishes to retain FLG to provide and FLG wishes to provide such services to Client on the terms set forth herein; and
WHEREAS, FLG has been continuously retained by Client since June 3, 2020; and
WHEREAS, the parties hereto wish to extend the term of the Agreement;
NOW, THEREFORE, in consideration of the mutual covenants set forth herein, the parties hereto agree as follows:

    Page 1 of #NUM_PAGES#    201210 FLG-Angion Second Amendment to Agreement (FLG redline).doc

SECOND AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT

1.Additional Compensation.      Exhibit A of the Agreement is amended to delete paragraph 7 in its entirety and replace it with the following language: 
“7. Additional Compensation: Additional Compensation shall consistent of two non-qualified common stock purchase option grants (the “Options”): one granted as of August 31, 2020 in an amount equal to 36,000 shares (the “First Options”), and a second granted as of December 9, 2020 in an amount equal to 108,000 shares (the “Second Options”). The exercise price per share all of the Options (as determined by Client’s Board of Directors) shall be computed pursuant to and consistent with Client’s IRC §409A per share common stock valuation (the “Common Stock Value”) applicable the grant date for each Option. With respect to the First Options, nine thousand (9,000) of such First Options shall be vested upon grant, with the balance vesting ratably over the subsequent nine (9) months. Vesting of the First Options shall cease upon termination of the Agreement, and the First Options shall be exercisable for one (1) year after termination of the Agreement.  With respect to the Second Options, all the Second Options shall commence vesting on June 1, 2021, at a rate of three thousand (3,000) per month, and shall cease vesting upon the earlier of (i) the termination of the Agreement, or (ii) the first month anniversary after the Client’s employment of a full time Chief Financial Officer.  Vested Second Options shall be exercisable for ninety (90) days after termination of the Agreement.  
Subject to compliance with applicable federal and state securities laws and regulations, all Options shall be issued 95% in the name of FLG Member and 5% in the name of FLG, each rounded to the nearest whole number of shares subject to the Options.”
2.Miscellaneous.    All other terms and conditions of the Agreement remain unchanged.  This Second Amendment shall be incorporated in the Agreement as Exhibit C.
IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Effective Date.

						
	CLIENT:
Angion Biomedica Corp.,
a Delaware corporation.
By:    Jay Venkatesan
Signed:        
Title:    Chief Executive Officer 
Address: 51 Charles Lindbergh Boulevard, 
Uniondale, New York  11553
Tel:    (415) 655-4899
Email:    jrv@angion.com
	FLG:
FLG Partners, LLC, 
a California limited liability company.
By:    Jeffrey S. Kuhn
Signed:        
Title:    Managing Partner

Effective Date:    _____________________.

    Page 2 of #NUM_PAGES#    201210 FLG-Angion Second Amendment to Agreement (FLG redline).docDocument

THIRD AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT

This third amendment (the “Third Amendment”) to the Confidential Consulting Agreement dated June 3, 2020 (the “Agreement”) by and between the parties hereto, is executed as of the date shown on the signature page (the “Effective Date”), by and between FLG Partners, LLC, a California limited liability company (“FLG”), and Angion Biomedica Corporation (“Client”). Capitalized terms used herein without definition shall have the meanings ascribed to them in the Agreement
RECITALS
WHEREAS, the parties hereto wish to amend the Agreement;
WHEREAS, Client wishes to retain FLG to provide and FLG wishes to provide such services to Client on the terms set forth herein; and
WHEREAS, FLG has been continuously retained by Client since June 3, 2020; and
WHEREAS, the parties hereto wish to extend the term of the Agreement;
NOW, THEREFORE, in consideration of the mutual covenants set forth herein, the parties hereto agree as follows:

    Page 1 of #NUM_PAGES#    220311 FLG-Angion Third Amendment.docx

THIRD AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT

1.Term.      The term of the Agreement is hereby extended until terminated by either party upon 15 days’ written notice to the other.
2.Fee.      $550 per hour, effective March 14, 2022.
3.Miscellaneous.    All other terms and conditions of the Agreement remain unchanged.  This Third Amendment shall be incorporated in the Agreement as Exhibit D.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the Effective Date.

						
	CLIENT:
Angion Biomedica Corp.,
a Delaware corporation.
By:    Jay Venkatesan
Signed:        
Title:    Chief Executive Officer 
Address: 51 Charles Lindbergh Boulevard, 
Uniondale, New York  11553
Tel:    (415) 655-4899
Email:    jrv@angion.com
	FLG:
FLG Partners, LLC, 
a California limited liability company.
By:    U. Heather Ogan
Signed:        
Title:    Administrative Partner

Effective Date:    March 17, 2022.

    Page 2 of #NUM_PAGES#    220311 FLG-Angion Third Amendment.docxDocument

Revised March 2021

ANGION BIOMEDICA CORP.

NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM

Non-employee members of the board of directors (the “Board”) of Angion Biomedica Corp. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), which is being adopted pursuant to the Board’s resolutions on January 25, 2021 and March 8, 2021.  The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.  This Program shall remain in effect until it is revised or rescinded by further action of the Board.  This Program may be amended, modified or terminated by the Board at any time, without advance notice, in its sole discretion.  The terms and conditions of this Program shall supersede any prior cash and/or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors.  This Program shall be effective upon the effectiveness of the registration statement for the Company’s initial public offering (the “Effective Date”).
1.    Cash Compensation.  
(a)    Annual Retainers.  Each Non-Employee Director shall be eligible to receive an annual retainer of $40,000 for service on the Board.  
(b)    Additional Annual Retainers.  In addition, a Non-Employee Director shall receive the following annual retainers:
(i)    Non-Executive Chairman of the Board.  A Non-Employee Director serving as the Non-Executive Chairman of the Board shall receive an additional annual retainer of $35,000 for such service.
(ii)    Lead Director of the Board.  A Non-Employee Director serving as the Lead Director of the Board shall receive an additional annual retainer of $20,000 for such service.
(iii)    Audit Committee.  A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service.  A Non-Employee Director serving as a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $7,500 for such service.
(iv)    Compensation Committee.  A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $10,000 for such service.  A Non-Employee Director serving as a member of the Compensation Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service.
(v)     Nominating and Corporate Governance Committee.  A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $8,000 for such service.  A Non-Employee Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service.
        (c)    Payment of Retainers.  The annual retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth (15th) day following the end of each calendar quarter.  In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.

|US-DOCS\116488861.4||

2.    Equity Compensation.  Non-Employee Directors shall be granted the equity awards described below.  The awards described below shall be granted under and shall be subject to the terms and provisions of the Company’s 2021 Equity Incentive Award Plan, as amended from time to time, or any other applicable Company equity incentive plan then-maintained by the Company (in any case, the “Equity Plan”) and shall be evidenced by the execution and delivery of award agreements in substantially the forms approved by the Board from time to time.  All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan.  
    (a)    Initial Awards.  Each Non-Employee Director who is initially elected or appointed to the Board after the Effective Date shall automatically be granted, on the date of such initial election or appointment, an option (an “Initial Award”) to purchase 30,000 shares of the Company’s common stock (“Shares”).  No Non-Employee Director shall be granted more than one Initial Award.  
    (b)    Subsequent Awards.  A Non-Employee Director who (i) has been serving on the Board immediately prior to any annual meeting of the Company’s stockholders after the Effective Date and (ii) will continue to serve as a Non-Employee Director immediately following such meeting, shall be automatically granted, on the date of such annual meeting, an option (a “Subsequent Award”) to purchase 15,000 Shares.
        
(c)    Termination of Service of Employee Directors.  Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their service with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(a) above, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from service with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(b) above.  
(d)    Terms of Awards Granted to Non-Employee Directors
        (i)    Purchase Price.  The per Share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a Share on the date the option is granted.  Without limiting the foregoing, Fair Market Value as of the Effective Date shall be equal to the price per Share to the public in the Company’s initial public offering, as set forth on the cover of the final prospectus of the initial public offering of Company common stock. 
        (ii)    Vesting.  Subject to Section 2(d)(iii) below, each Initial Award shall vest and become exercisable in thirty-six (36) substantially equal installments on each monthly anniversary of the date of grant, subject to the Non-Employee Director continuing to provide services to the Company through each such vesting date.  Subject to Section 2(d)(iii) below, each Subsequent Award shall vest and become exercisable in full on the earlier of the one year anniversary of the date of grant and the next annual meeting of the Company’s stockholders after the grant date, subject to the Non-Employee Director continuing to provide services to the Company through such vesting date.  
(iii)    Accelerated Vesting.  
(A) Termination Due to Death or Disability.  In the event that any Non-Employee Director incurs a Termination of Service (as defined in the Equity Plan) due to such Non-Employee Director’s death or Disability (as defined the Equity Plan), each of such Non-Employee Director’s Initial Award and Subsequent Award(s), along with any other stock options or other equity-based awards held by such Non-Employee Director, shall vest and, if applicable, become exercisable with respect to one hundred percent (100%) of the Shares subject thereto upon such Termination of Service.  
(B)    Change in Control.  In the event that a Change in Control (as defined in the Equity Plan) occurs, each Initial Award and Subsequent Award, along with any other stock options or other equity-based awards held by any Non-Employee Director, shall vest 
2

|US-DOCS\116488861.4||

and, if applicable, become exercisable with respect to one hundred percent (100%) of the Shares subject thereto as of immediately prior to such Change in Control.
(iv)    Term.  The term of each stock option granted to a Non-Employee Director shall be ten (10) years from the date the option is granted. 
3.    Reimbursements.  The Company shall reimburse each Non-Employee Director for all reasonable, documented, out-of-pocket travel and other business expenses incurred by such Non-Employee Director in the performance of his or her duties to the Company in accordance with the Company’s applicable expense reimbursement policies and procedures as in effect from time to time. 
* * * * *
3

|US-DOCS\116488861.4||

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]